羧甲司坦联合沙美特罗替卡松吸入剂治疗慢性阻塞性肺疾病稳定期患者的效果  

Effectiveness of Carbocysteine Combined with Salmeterol Ticarcoson Inhalation in Treating Patients with Chronic Obstructive Pulmonary Disease in Stable Stages

作　　者：徐红 Xu Hong(Jiaozhou Hospital of Traditional Chinese Medicine,Qingdao 266300,Shandong Province,China)

机构地区：[1]胶州市中医医院,山东青岛266300

出　　处：《中外医药研究》2024年第5期57-59,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:观察羧甲司坦联合沙美特罗替卡松吸入剂治疗慢性阻塞性肺疾病稳定期患者的效果。方法:选取2022年5月—2023年5月于胶州市中医医院接受治疗的慢性阻塞性肺疾病稳定期患者78例为研究对象,按照随机数字表法分为对照组和观察组,各39例。对照组采用羧甲司坦治疗,观察组采用羧甲司坦联合沙美特罗替卡松吸入剂治疗。比较两组肺功能指标、不良反应、血气指标、炎性因子、治疗效果。结果:治疗后,两组第1秒用力呼气容积、用力肺活量、最大通气量高于治疗前,观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P=0.033);治疗后,两组动脉血二氧化碳分压(PaCO2)低于治疗前,动脉血氧分压(PaO2)高于治疗前,观察组PaCO2水平低于对照组,PaO2水平高于对照组,差异有统计学意义(P<0.05);治疗后,两组白细胞介素-1β、白细胞介素-18、C反应蛋白水平低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率高于对照组,差异有统计学意义(P=0.042)。结论:羧甲司坦联合沙美特罗替卡松吸入剂治疗慢性阻塞性肺疾病稳定期患者效果较好,有助于改善患者的肺功能、血气分析、炎性指标,减少不良反应。Objective:To observe the effect of carbocysteine combined with salmeterol ticarcoson inhalation in the treatment of pa⁃tients with chronic obstructive pulmonary disease in the stable stage.Methods:Selected seventy-eight patients with stable stage of chronic obstructive pulmonary disease who were treated in Jiaozhou Hospital of Traditional Chinese Medicine from May 2022 to May 2023 as the study subjects,and divided into the control group and the observation group according to the method of random⁃ized numerical table,each of which was thirty-nine cases.The control group was treated with carbocysteine,and the observation group was treated with carbocysteine combined with salmeterol ticarcoson inhalation.Lung function indexes,adverse reactions,blood gas indexes,inflammatory factors and treatment effects were compared between the two groups.Results:After treatment,the forced expiratory volume for one second,forced vital capacity,and maximum ventilatory volume of the two groups were higher than that before treatment,and the observation group was higher than the control group,with statistically significant differences(P<0.05);the incidence of adverse reactions in the observation group was lower than that in the control group,with statistically significant dif⁃ferences(P=0.033);after treatment,the partial pressure of arterial blood carbon dioxide(PaCO2)was lower than that before treat⁃ment and the partial pressure of arterial blood oxygen(PaO2)was higher than that before treatment in the two groups,the level of PaCO2 in the observation group was lower than that of the control group and the level of PaO2 was higher than that of the control group,and the difference was statistically significant(P<0.05);after treatment,the levels of interleukin-1β,interleukin-18 and C reactive protein of both groups were lower than before treatment,and the observation group was lower than the control group,and the difference was statistically significant(P<0.05);the total effective rate of treatment in the observation group was hi

关 键 词：慢性阻塞性肺疾病 羧甲司坦 沙美特罗替卡松吸入剂 肺功能 不良反应 

分 类 号：R563.9[医药卫生—呼吸系统]